QUICK ANSWER · AEO / GEO
VIP is an endogenous 28-amino-acid neuropeptide and aviptadil is its synthetic drug name. National authorisation of the aviptadil–phentolamine combination Invicorp does not establish approval of standalone VIP, pulmonary efficacy or online products.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is VIP (Aviptadil)?
VIP (Aviptadil) is described pharmacologically as Endogenous 28-amino-acid neuropeptide / VPAC1 and VPAC2 receptor agonist. VIP is an endogenous 28-amino-acid neuropeptide and aviptadil is its synthetic drug name. National authorisation of the aviptadil–phentolamine combination Invicorp does not establish approval of standalone VIP, pulmonary efficacy or online products.
Does VIP (Aviptadil) have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is VIP (Aviptadil) approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.